Cytokinetics Management
Management criteria checks 3/4
Cytokinetics' CEO is Robert Blum, appointed in Feb 2006, has a tenure of 18.75 years. total yearly compensation is $8.75M, comprised of 9% salary and 91% bonuses, including company stock and options. directly owns 0.23% of the company’s shares, worth $13.44M. The average tenure of the management team and the board of directors is 3.6 years and 11.8 years respectively.
Key information
Robert Blum
Chief executive officer
US$8.8m
Total compensation
| CEO salary percentage | 9.0% |
| CEO tenure | 18.8yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.6yrs |
| Board average tenure | 11.8yrs |
Recent management updates
Recent updates
Cytokinetics: On The Cusp Of Commercialization
Nov 14Cytokinetics: Aficamten Rolling NDA Submission Leads To Expansion Opportunities
Aug 13Is Cytokinetics (NASDAQ:CYTK) Weighed On By Its Debt Load?
Aug 11
Cytokinetics' Aficamten: Heartfelt Potential Amid Market Woes
Jul 24Cytokinetics Decides To Go It Alone
May 24Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being
May 09Cytokinetics, Incorporated: Buyout Speculation Persists
Apr 01Cytokinetics: CEO Talks Down Buyout Prospects
Mar 16Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)
Jan 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$576m |
| Jun 30 2024 | n/a | n/a | -US$545m |
| Mar 31 2024 | n/a | n/a | -US$531m |
| Dec 31 2023 | US$9m | US$790k | -US$526m |
| Sep 30 2023 | n/a | n/a | -US$527m |
| Jun 30 2023 | n/a | n/a | -US$540m |
| Mar 31 2023 | n/a | n/a | -US$431m |
| Dec 31 2022 | US$9m | US$742k | -US$389m |
| Sep 30 2022 | n/a | n/a | -US$282m |
| Jun 30 2022 | n/a | n/a | -US$216m |
| Mar 31 2022 | n/a | n/a | -US$258m |
| Dec 31 2021 | US$6m | US$709k | -US$215m |
| Sep 30 2021 | n/a | n/a | -US$229m |
| Jun 30 2021 | n/a | n/a | -US$156m |
| Mar 31 2021 | n/a | n/a | -US$135m |
| Dec 31 2020 | US$5m | US$682k | -US$127m |
| Sep 30 2020 | n/a | n/a | -US$114m |
| Jun 30 2020 | n/a | n/a | -US$140m |
| Mar 31 2020 | n/a | n/a | -US$132m |
| Dec 31 2019 | US$3m | US$656k | -US$122m |
| Sep 30 2019 | n/a | n/a | -US$118m |
| Jun 30 2019 | n/a | n/a | -US$110m |
| Mar 31 2019 | n/a | n/a | -US$105m |
| Dec 31 2018 | US$3m | US$630k | -US$106m |
| Sep 30 2018 | n/a | n/a | -US$120m |
| Jun 30 2018 | n/a | n/a | -US$131m |
| Mar 31 2018 | n/a | n/a | -US$132m |
| Dec 31 2017 | US$3m | US$612k | -US$128m |
Compensation vs Market: Robert's total compensation ($USD8.75M) is about average for companies of similar size in the US market ($USD7.78M).
Compensation vs Earnings: Robert's compensation has increased whilst the company is unprofitable.
CEO
Robert Blum (60 yo)
18.8yrs
Tenure
US$8,751,057
Compensation
Mr. Robert I. Blum has been Chief Executive Officer, President and Director of Cytokinetics, Incorporated since January 22, 2007 and served as its Principal Financial Officer until May 08, 2024. Mr. Blum p...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 18.8yrs | US$8.75m | 0.23% $ 13.4m | |
| VP & Chief Accounting Officer | 5.5yrs | US$1.04m | 0.0063% $ 366.8k | |
| Executive Vice President of Research & Development | 12.4yrs | US$4.44m | 0.053% $ 3.1m | |
| Executive VP & Chief Commercial Officer | 3.7yrs | US$3.20m | 0.021% $ 1.2m | |
| Co-Founder & Member of Scientific Advisory Board | 27.3yrs | US$21.94k | no data | |
| Executive VP & CFO | less than a year | no data | no data | |
| Vice President of Sales & Operations | 3.2yrs | no data | no data | |
| Vice President of Corporate Finance and Financial Planning & Analysis | less than a year | no data | no data | |
| Senior Vice President of Global Supply Chain Operations & Technical Operations | no data | no data | no data | |
| VP & Chief Compliance Officer | 3yrs | no data | no data | |
| VP, Associate General Counsel & Corporate Secretary | no data | no data | no data | |
| Senior Vice President of Global Marketing & Commercial Strategy | 3.5yrs | no data | no data |
3.6yrs
Average Tenure
60yo
Average Age
Experienced Management: CYTK's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 17.8yrs | US$8.75m | 0.23% $ 13.4m | |
| Co-Founder & Member of Scientific Advisory Board | no data | US$21.94k | no data | |
| Independent Director | 11.8yrs | US$529.02k | 0.013% $ 736.5k | |
| Co-Founder & Chairman of Scientific Advisory Board | 16.6yrs | US$41.50k | no data | |
| Independent Director | 4yrs | US$519.02k | 0.015% $ 853.5k | |
| Independent Chairman | 15.8yrs | US$559.02k | 0.028% $ 1.6m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 8.3yrs | US$942.23k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.8yrs | US$509.02k | 0.010% $ 590.5k |
11.8yrs
Average Tenure
68yo
Average Age
Experienced Board: CYTK's board of directors are seasoned and experienced ( 11.8 years average tenure).